Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.98 -0.62 (-1.04%)
Streaming Delayed Price Updated: 2:16 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma. 
Via Benzinga
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy. 
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
Exposures Political
Nuclear Power Is Solving the World’s Looming Energy Crisis
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off. 
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
My “Two-Step” Plan for Surviving Shaky Markets – and Coming Out Ahead
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off. 
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
From Bristol Myers Squibb
Via Business Wire
How to Read Trump’s Tariff Playbook – and Prepare for His Next Moves
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off. 
Via InvestorPlace
Topics Government World Trade
Exposures Political Tariff
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for. 
Via StockStory
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
Gapping S&P500 stocks in Monday's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand its reach in B-cell cancers. 
Via Benzinga
Exposures Product Safety
Royalty Pharma Earnings: What To Look For From RPRX
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
From Bristol Myers Squibb
Via Business Wire
MarketBeat Week in Review – 02/03 - 02/07
Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets. 
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Interest Rates Tariff
Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying opportunity 
Via MarketBeat
US Stocks Likely To Open On A Mixed Note: Amazon, Pinterest, Take-Two Among Stocks To Watch
U.S. stocks could open mixed on Friday. Newell Brands, Flowers Foods, and Plains All American Pipeline to report earnings. 
Via Benzinga
S&P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
Bristol Myers Squibb Tops Q4 Estimates
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations. 
Via The Motley Fool
Bristol-Myers Squibb Stock Slides On Weak 2025 Outlook, Retail Steps In To Buy The Dip
The company announced plans to generate $2 billion in annual cost savings by the end of 2027. 
Via Stocktwits
Wondering what's happening in today's S&P500 pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid generic headwinds and cost-saving plans. 
Via Benzinga
Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%.
Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.